Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Natural Product Expo W...Natural Product Expo West
Not Confirmed
Not Confirmed
03-06 March, 2026
Natural Products ExpoNatural Products Expo
Not Confirmed
Not Confirmed
03-06 March, 2026
Pharma & Device Packag...Pharma & Device Packaging
Not Confirmed
Not Confirmed
04-05 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Natural Product Expo West
Not Confirmed
Contact SupplierNatural Product Expo West
Natural Product Expo W...Natural Product Expo West
Industry Trade Show
Not Confirmed
03-06 March, 2026
Natural Products ExpoNatural Products Expo
Industry Trade Show
Not Confirmed
03-06 March, 2026
Pharma & Device Packag...Pharma & Device Packaging
Industry Trade Show
Not Confirmed
04-05 March, 2026
Digital content
NEWS #PharmaBuzz
25 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/25/3245096/0/en/LENSAR-Provides-Update-on-Pending-Acquisition-by-Alcon.html
17 Feb 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-02-17/alcon-launches-total30-multifocal-for-astigmatism-the-world-s-only-monthly-multifocal-toric-contact
02 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260202959725/en/Alcon-Debuts-Groundbreaking-PRECISION7-in-Canada-a-One-Week-Replacement-Contact-Lens-to-Start-and-End-Every-Week-Fresh
07 Jan 2026
// FIERCE BIOTECH
https://www.fiercebiotech.com/medtech/staar-surgicals-takeover-saga-ends-shareholder-revolt-stops-alcons-attempted-merger-deal
06 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260106924852/en/STAAR-Surgical-Announces-Preliminary-Results-of-Special-Meeting-of-Stockholders
19 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251219413594/en/Broadwood-Partners-Denounces-STAAR-Surgicals-Fourth-Delay-of-the-Shareholder-Vote-on-the-Companys-Proposed-Sale-to-Alcon
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6987
Submission : 1987-05-19
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2059
Submission : 1973-01-12
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 761
Submission : 1964-01-09
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 988
Submission : 1966-09-14
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2336
Submission : 1974-10-24
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
NDC Package Code : 70727-324
Start Marketing Date : 2017-12-18
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6987
Submission : 1987-05-19
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2059
Submission : 1973-01-12
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 761
Submission : 1964-01-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 988
Submission : 1966-09-14
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2336
Submission : 1974-10-24
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
NDC Package Code : 70727-324
Start Marketing Date : 2017-12-18
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Drugs in Development
Details:
Netarsudil is a Small Molecule drug, which is currently being evaluated in Phase IV clinical studies for the treatment of Glaucoma, Open-Angle.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Recipient: Mayo Clinic
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2026
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Recipient : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Netarsudil is a Small Molecule drug, which is currently being evaluated in Phase IV clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 08, 2026
Details:
Systane Pro (hyaluronate) is a carbohydrate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Dry Eye Syndromes.
Lead Product(s): Sodium Hyaluronate,Perfluorohexyloctane
Therapeutic Area: Ophthalmology Brand Name: Systane Pro
Study Phase: Phase IVProduct Type: Carbohydrate
Recipient: Indiana University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2025
Lead Product(s) : Sodium Hyaluronate,Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Recipient : Indiana University
Deal Size : Inapplicable
Deal Type : Inapplicable
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
Details : Systane Pro (hyaluronate) is a carbohydrate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Systane Pro
Product Type : Carbohydrate
Upfront Cash : Inapplicable
November 21, 2025
Details:
Netarsudil is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Glaucoma.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Recipient: Oregon Health and Science University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2025
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Rocklatan Retinal Perfusion OCT Study
Details : Netarsudil is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Glaucoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 16, 2025
Details:
Netarsudil is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Ocular Hypertension.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 24, 2025
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Details : Netarsudil is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Ocular Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 24, 2025
Details:
Tryptyr (acoltremon) is a TRPM8 thermoreceptor agonist indicated for the treatment of the signs and symptoms of dry eye disease.
Lead Product(s): Acoltremon
Therapeutic Area: Ophthalmology Brand Name: Tryptyr
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2025
Lead Product(s) : Acoltremon
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alcon Wins FDA Approval for TRYPTYR for Signs and Symptoms of Dry Eye Disease
Details : Tryptyr (acoltremon) is a TRPM8 thermoreceptor agonist indicated for the treatment of the signs and symptoms of dry eye disease.
Product Name : Tryptyr
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2025
Details:
Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001 for the treatment of Corneal Edema in adult.
Lead Product(s): Neltependocel
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cell & Gene Therapy
Recipient: Aurion Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 26, 2025
Lead Product(s) : Neltependocel
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Recipient : Aurion Biotech
Deal Size : Undisclosed
Deal Type : Acquisition
Alcon Acquires Aurion Biotech To Advance Corneal Cell Therapy
Details : Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001 for the treatment of Corneal Edema in adult.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
March 26, 2025
Details:
Systane Pro PF (propylene glycol) is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes.
Lead Product(s): Mono Propylene Glycol
Therapeutic Area: Ophthalmology Brand Name: Systane Pro PF
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2025
Lead Product(s) : Mono Propylene Glycol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alcon Launches New Systane PRO Preservative-Free in The US
Details : Systane Pro PF (propylene glycol) is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes.
Product Name : Systane Pro PF
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2025
Details:
HYDROXYPROPYLMETHYLCELLULOSE is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): HYDROXYPROPYLMETHYLCELLULOSE,Non-Lipid Artificial Tear
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Carbohydrate
Recipient: University of Seville
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 20, 2025
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Non-Lipid Artificial Tear
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : University of Seville
Deal Size : Inapplicable
Deal Type : Inapplicable
Immediate Effects of Lipid-Based and Non-Lipid Artificial Tears on Corneal Aberrations
Details : HYDROXYPROPYLMETHYLCELLULOSE is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
January 20, 2025
Details:
Systane Complete is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Systane Complete
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Dietary Supplement
Recipient: National Taiwan University Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2025
Lead Product(s) : Systane Complete
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Systane Complete is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 08, 2025
Details:
This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Undisclosed
Recipient: Southern College of Optometry
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Recipient : Southern College of Optometry
Deal Size : Inapplicable
Deal Type : Inapplicable
Treating Lid Wiper Epitheliopathy
Details : This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 04, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
Alcon Inc is a supplier offers 6 products (APIs, Excipients or Intermediates).
Find a price of Chlorhexidine Gluconate bulk offered by Alcon Inc
Find a price of Dodecyl Sulfate bulk offered by Alcon Inc
Find a price of STEROID/ANTI-INFECTIVE OPHTH.COMBINATIONS;SAFETY/EFFICACY ANALYSIS bulk offered by Alcon Inc
Find a price of FACILITIES AND CONTROLS bulk offered by Alcon Inc
Find a price of DAROIL INVESTIGATORS bulk offered by Alcon Inc
Find a price of Netarsudil Mesylate bulk offered by Alcon Inc
Share 
